Skip to content

Impact of Shenmai in microRNA-126 level of elderly patients with preserved ejection fraction heart failure

Study on the effect of Shenmai Injection in the adjuvant treatment of preserving ejection fraction in heart failure

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058034
Enrollment
Unknown
Registered
2022-03-27
Start date
2022-04-15
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

Experimental group:Shenmai injection+medicine+exercise rehailitation
Control group:Medicine+exercise rehabilitation

Sponsors

Tongde Hospital of Zhejiang Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis of Western medicine must comply with the clinical diagnostic criteria of preserved heart failure in the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure revised by the Chinese Medical Association in 2018; 2. TCM syndrome differentiation conforms to the syndrome of deficiency of Qi and Yin and withdrawal of blood stasis and water in Guiding Principles for Clinical Research of New Chinese Medicines; 3. Aged from 18 to 75 years; 4. According to the New York Heart Association (NYHA) cardiac function grading standard, patients with grade II to III heart function and relatively stable condition were retained with ejection fraction; 5. The patients volunteered to join the study.

Exclusion criteria

Exclusion criteria: 1. Patients with unstable angina pectoris, active myocarditis and acute myocardial infarction within 4 weeks; 2. Patients with cardiac insufficiency caused by congenital heart disease, valvular heart disease and thyroid disease; 3. Factors that increase mortality, such as cardiogenic shock, complete atrioventricular block, severe ventricular arrhythmia, pulmonary embolism, constrictive pericarditis, and obvious infection; 4. Pregnant or lactating patients; 5. Allergic patients who have known the drug ingredients in this study; 6. Participated in other experiments or took drugs that affected the results of this experiment before enrollment; 7. Severe diseases of brain, liver, kidney, endocrine system and blood system; 8. Mental illness and inability to cooperate with a treating observer.

Design outcomes

Primary

MeasureTime frame
cardiac function;microRNA-126;

Countries

China

Contacts

Public ContactJin Dong

Tongde Hospital of Zhejiang Province

jindong1980@sina.com+86 13958133668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026